L-Alaninamide,N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-[(2,6-dichlorobenzoyl)oxy]-1-(2-ethoxy-2-oxoethyl)-2-oxopropyl]-(9CI) Chemical Properties

Boiling point:

861.9±65.0 °C(Predicted)

Density 

1.299±0.06 g/cm3(Predicted)

storage temp. 

Store at -20°C

pka

11.05±0.46(Predicted)

form 

Solid

color 

White to off-white

L-Alaninamide,N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-[(2,6-dichlorobenzoyl)oxy]-1-(2-ethoxy-2-oxoethyl)-2-oxopropyl]-(9CI) Usage And Synthesis

Biological Activity

SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM)[1][2]. SDZ 224-015 (0.3-300 μg/kg) potently reduces carrageenin-induced paw oedema[2].SDZ 224-015 (0.2-5 mg/kg, p.o.) displays analgesic activity in the Randall-Selitto yeast-inflamed paw pressure test, significant at a dose of 1 mg/kg[2].

References

[1]. Martin A Redhead, et al. Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Sci Rep. 2021 Jun 24;11(1):13208. [2]. P R Elford, et al. Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115(4):601-6.

L-Alaninamide,N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-[(2,6-dichlorobenzoyl)oxy]-1-(2-ethoxy-2-oxoethyl)-2-oxopropyl]-(9CI)(161511-45-1)Related Product Information

• Z-VDVAD-AFC
• Z-YVAD-AFC
• Z-VEID-AFC
• Z-TYR-SER-OH
• UROKINASE SUBSTRATE I, COLORIMETRIC
• Z-VAL-ALA-ASP-AMC
• BENZYLOXYCARBONYL-L-VALYL-L-LYSYL-L-METHIONINE 4-METHYLCOUMARYL-7-AMIDE HYDROCHLORIDE
• Z-TYR-VAL-ALA-ASP-CHLOROMETHYLKETONE
• Z-VAL-LYS-LYS-ARG-AFC
• Z-VRPR-FMK (trifluoroacetate salt)
• Z-VAL-VAL-ARG-AMC
• Z-VAL-ALA-ASN-AMC